Replimune Faces Investor Lawsuit Following FDA's Drug Approval Block Replimune is facing legal action from investors after FDA blocks its cancer drug RP1, triggering significant stock drops and allegations of misrepresentation.

Replimune Faces Investor Lawsuit Following FDA's Drug Approval Block #United_States #San_Francisco #Replimune #RP1 #FDA_Block